What is the appropriate management of epididymo‑orchitis in a 65‑year‑old man with benign prostatic hyperplasia and no sexual risk factors?

Management of Epididymo-orchitis in a 65-Year-Old with BPH and No Sexual Risk Factors

In a 65-year-old man with BPH and no sexual promiscuity, treat epididymo-orchitis with a fluoroquinolone (ofloxacin or levofloxacin) as monotherapy targeting enteric organisms, as this age group with bladder outlet obstruction typically has infection from gram-negative uropathogens rather than sexually transmitted infections.

Pathophysiology and Risk Stratification

In men over 35 years, particularly those with BPH, epididymo-orchitis is predominantly caused by enteric organisms (E. coli and other gram-negative bacteria) rather than sexually transmitted pathogens 1, 2. The bladder outlet obstruction from BPH creates urinary stasis and reflux, predisposing to ascending infection from uropathogens 1.

Key clinical distinction: Age and sexual history determine the causative organism:

• Under 35 years OR sexually active with risk factors: Chlamydia trachomatis and Neisseria gonorrhoeae
• Over 35 years with BPH and no sexual risk: Enteric gram-negative organisms

Diagnostic Workup

Obtain the following tests to confirm diagnosis and guide therapy:

• Mid-stream urine culture and sensitivity - Essential to identify the causative organism and antibiotic susceptibilities 2, 3
• Urinalysis - Screen for pyuria and bacteriuria
• Scrotal ultrasound with Doppler - If diagnosis uncertain or to exclude testicular torsion, abscess formation, or tumor 4

Do NOT routinely obtain:

• Urethral swabs for gonorrhea/chlamydia PCR (not indicated without sexual risk factors) 3
• Serum creatinine unless there are signs of upper tract involvement or renal insufficiency

Antibiotic Treatment

First-Line Therapy (Enteric Organism Coverage)

Prescribe either:

• Ofloxacin 200-400 mg orally twice daily for 10-14 days, OR
• Levofloxacin 500 mg orally once daily for 10-14 days 2, 5

These fluoroquinolones provide:

• Excellent penetration into epididymal and testicular tissue
• Broad gram-negative coverage including E. coli
• Once or twice daily dosing for compliance

Important Caveat on Fluoroquinolone Resistance

Rising ciprofloxacin resistance in E. coli (particularly in Europe and USA) makes empiric ciprofloxacin less reliable 1. Ofloxacin or levofloxacin are preferred over ciprofloxacin for better coverage. If local resistance patterns show high fluoroquinolone resistance, consider alternative agents based on culture results.

Alternative Agents (If Fluoroquinolones Contraindicated)

If fluoroquinolones cannot be used (allergy, tendon disorders, or high local resistance):

• Await culture results and tailor therapy to sensitivities
• Consider trimethoprim-sulfamethoxazole if organism is susceptible
• Third-generation cephalosporins have poor epididymal penetration and are suboptimal

Adjunctive Management

Supportive measures:

• Scrotal elevation and support
• NSAIDs for pain and inflammation (e.g., ibuprofen 400-600 mg three times daily)
• Ice packs to reduce swelling
• Bed rest during acute phase

Follow-Up and BPH Management

Short-Term (2-4 weeks)

• Reassess for symptom resolution
• If no improvement, obtain urine culture and consider imaging to exclude abscess or alternative diagnosis 6

Long-Term BPH Evaluation

This patient requires urological assessment for his underlying BPH to prevent recurrent infections 1:

• Uroflowmetry and post-void residual - Assess degree of obstruction
• Prostate size assessment (DRE, PSA as proxy, or ultrasound if intervention planned)
• Consider medical therapy:
  • Alpha-blockers (tamsulosin, alfuzosin) for symptom relief
  • 5-alpha-reductase inhibitors (finasteride, dutasteride) if prostate is enlarged to reduce progression risk 7, 8
• Surgical intervention may be needed if severe obstruction, recurrent retention, or recurrent UTIs/epididymo-orchitis

Critical Pitfalls to Avoid

1. Do not use doxycycline or ceftriaxone monotherapy in this patient - these target STIs, not enteric organisms 2, 5

2. Do not prescribe ciprofloxacin reflexively - resistance patterns make ofloxacin/levofloxacin superior choices 1

3. Do not ignore the underlying BPH - failure to address bladder outlet obstruction leads to recurrent infections 1

4. Do not assume sexual transmission - while possible at any age 9, the clinical context (BPH, no risk factors) makes enteric organisms far more likely

5. Do not undertake prolonged or repeated antibiotic courses without culture guidance - this promotes resistance 10

When to Refer to Urology

Immediate referral if:

• Suspected testicular torsion (requires emergency exploration)
• Abscess formation on imaging
• Sepsis or systemic toxicity

Routine referral for:

• All men over 50 with epididymo-orchitis to evaluate and manage underlying BPH 1
• Recurrent episodes despite appropriate treatment
• Persistent symptoms after 2 weeks of appropriate antibiotics